885053-97-4

885053-97-4 structure

885053-97-4 structure

Name: Panobacumab
Chemical Name: Panobacumab
CAS Number: 885053-97-4
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Anti-infection Bacterial
Create Date: 2022-10-31 07:58:35
Modify Date: 2024-01-03 07:41:23
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa[1].

Name	Panobacumab

Description	Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa[1].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> Bacterial
In Vitro	Panobacumab (KBPA101) strongly binds to 18 of 20 clinical O11 isolates, functional avidity of KBPA101 to O11 LPS determined by inhibition ELISA is 5.81×107 M-1± 2.8×107 M-1[1]. Panobacumab (KBPA101) (0.0001-100 ng/mL; 2 h) specifically mediates complement-dependent opsonophagocytosis of P. aeruginosa serotype O11 with an IC50 of 0.16 ng/mL[1]. Panobacumab (KBPA101) (0.1-10 ng/mL) shows direct complement-dependent killing of P. aeruginosa serotype O11 cells in a dose-dependent manner[1].
In Vivo	Panobacumab (KBPA101) (1-4 mg/kg; i.v.; once) protects mice from systemic infection with P. aeruginosa serotype O11 in a murine burn wound model[1]. Panobacumab (KBPA101) (0.005-0.4 mg/kg; i.v.; once) protects mice from local lung infection with P. aeruginosa serotype O11 in an acute lung infection model[1]. Animal Model: Female NMRI mice, murine burn wound model[1] Dosage: 1, 2, or 4 mg/kg Administration: Intravenous injection, single dose Result: Significantly reduced mortality compared to untreated control animals administered either immediately or 4 h postchallenge. Animal Model: BALB/c mice, acute lung infection model[1] Dosage: 0.005 to 0.4 mg/kg Administration: Intravenous injection, single dose Result: Led to rapid clearance of P. aeruginosa from the lung, completely cleared systemic P. aeruginosa from the spleen, whereas live bacteria were still present in untreated mice at 48 h postchallenge, showed milder macroscopic lung pathology at 6 and 24 h after infection.
References	[1]. Horn MP, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother. 2010 Jun;54(6):2338-44.

No Any Chemical & Physical Properties